CRELD1 Protein (His Tag)

Cysteine-rich with EGF-like domains 1 Protein Datasheet

CRELD1 Protein Product Information

• Synonym: CRELD1, CIRRIN
• Protein Construction: A DNA sequence encoding the human CRELD1 (NP_001070883.1) (Met1-Glu362) was expressed with a polyhistidine tag at the C-terminus.
• Source: Human
• Expression Host: Human Cells

CRELD1 Protein QC Testing

• Purity: > 95% as determined by SDS-PAGE
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Gln 30
• Molecular Mass: The recombinant human CRELD1 consists of 344 amino acids and predicts a molecular mass of 37.4 KDa. It migrates as an approximately 51 KDa band in SDS-PAGE under reducing conditions.
• Formulation: Lyophilized from sterile PBS, pH 7.4.
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: CRELD1 protein

CRELD1 Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

CRELD1 Protein Description

CRELD1 is an approximately 50 kDa transmembrane glycoprotein. It has an epidermal growth factor (EGF) like domain. EGF-like repeats are a class of cysteine-rich domains that mediate interactions between proteins of diverse function. EGF domains are found in proteins that are either completely secreted or have transmembrane regions that tether the protein to the cell surface. CRELD1 contains a 333 amino acid (aa) extracellular domain (ECD), two tandem transmembrane segments, and a second ECD of 15 aa. Defects in CRELD1 may cause susceptibility to atrioventricular septal defect type 2 which results in a persistent common atrioventricular canal.

References

1. Robinson SW. et al., 2003, Am J Hum Genet. 72 (4): 1047-52.
2. Zatyka M. et al., 2005, Clin Genet. 67 (6): 526-8.
3. Stelzl U. et al., 2005, Cell. 122 (6): 957-68.